Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

US FDA approves Lilly's Mounjaro to reduce cardiovascular risk

28 August 2026 · By · Wire by Fusion42

Published

28 August 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at reuters.com →

◆ Verified

Fusion42 · 29 August 2026 · Fusion42 review

The US FDA approved Eli Lilly's Mounjaro for reducing cardiovascular risk in adults with type 2 diabetes at high risk of heart attack or stroke, expanding its use beyond blood sugar control.

This Wire brief sits within Fusion42's coverage of Medtech, and 8 sources have reported it.

◆ ◆ The Wire takeaway

You can now pitch Mounjaro’s cardiovascular benefits to healthcare providers as a regulatory-approved advantage, opening new sales avenues beyond diabetes care.

◆ Coverage

8 sources · 28 Aug 2026

◆ Topics

Medtechfda-approvaldiabetescardiovascular-riskdrug-expansioneli-lilly